Jim Sullivan on Improving the Lives of Patients

At AbbVie, research and innovation are the cornerstones of our business as a global biopharmaceutical company. We focus on developing medicines that deliver strong clinical performance, provide more patient benefit and deliver economic value, particularly where there is significant need around the world in certain disease areas.  Arthritis is an example of a disease where we have the opportunity to continue to make headway to improve the lives of patients. According to the U.S. Centers for Disease Control and Prevention (CDC) prevalence of musculoskeletal diseases could increase from 52 million people in the U.S. to 67 million by 2030 if current trends continue.1 As an expert in autoimmune diseases and therapies, we are focused on developing new medicines to address chronic progressive diseases in the field of immunology. We are investigating several diseases which have few or no treatments, including osteoarthritis and lupus, and we are progressing next-generation therapies in rheumatoid arthritis with the objective to improve patient care. Our understanding of the pathophysiology of arthritis and related diseases is allowing us to explore new approaches.  We currently have five compounds in Phase 2 clinical development for rheumatoid arthritis. We recognize the importance of public-private partnerships in building our understanding of the pathophysiology of the disease and ensuring that development of therapies is focused on the needs of patients first and foremost. We ar...
Source: PHRMA - Category: Pharmaceuticals Authors: Source Type: news